Background Although coronavirus disease 2019 (COVID-19) is a mild infection in most
children, a small proportion develop severe or critical illness. Data describing agents with …

Background Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a
small proportion of pediatric patients develop severe or critical illness. Guidance is therefore …

OBJECTIVES: Remdesivir shortens time to recovery in adults with severe coronavirus
disease 2019 (COVID-19), but its efficacy and safety in children are unknown. We describe …

Children represent a minority of total COVID-19 cases, but studies have reported severe
disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated …

Following the emergence of the SARS-CoV-2 pandemic, finding efficient forms of treatment
is seen as a priority for both adults and children. On April 25, 2022, remdesivir has become …

We describe an ex-premature infant presenting with severe acute respiratory syndrome
coronavirus 2 infection in the fifth week of life. In current reports, researchers indicate that …

Objective To describe the clinical profiles and risk factors for critical illness in hospitalized
children and adolescents with coronavirus disease 2019 (COVID-19). Study design Children …

Most severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in pediatric
patients are mild or asymptomatic. However, infants have emerged at higher risk of …

Objectives: We sought to describe the presentation, course, and outcomes of hospitalized
pediatric coronavirus disease 2019 patients, with detailed description of those requiring …

Diagnosis and Treatment (the sixth edition) of COVID-19 [1] only provided potential antiviral
treatments in adults. According to the current guidelines for management in adults and …